Showing results (2231-2240 of 2,343) with videos related to

Sort By:
Pageof 235
NEJM Evidence|February 6, 2024
Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate CancerLaila A Gharzai, Ralph Jiang, Elizabeth M Jaworski, et al.
International Journal of Radiation Oncology, Biology, Physics|October 29, 2025
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical TrialKyle Wang, Allison M Deal, Colette J Shen, et al.
Sports Medicine (Auckland, N.Z.)|January 11, 2021
Factors Associated with Symptom Reporting in U.S. Service Academy Cadets and NCAA Student Athletes without Concussion: Findings from the CARE ConsortiumJaclyn B Caccese, Grant L Iverson, Katherine J Hunzinger, et al.
Nature Chemistry|May 23, 2014
A mitochondrial pathway for biosynthesis of lipid mediatorsYulia Y Tyurina, Samuel M Poloyac, Vladimir A Tyurin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601William C Jackson, Ming Tang, Matthew J Schipper, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|August 9, 2016
Refractory Status Epilepticus in Children: Intention to Treat With Continuous Infusions of Midazolam and PentobarbitalRobert C Tasker, Howard P Goodkin, Iván Sánchez Fernández, et al.
Journal of Medicinal Chemistry|May 14, 2010
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitorsShudong Wang, Carol A Midgley, Frederic Scaërou, et al.
Chemistry & Biology|November 2, 2010
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agentsShudong Wang, Gary Griffiths, Carol A Midgley, et al.
Pageof 235